Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Go back to Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus| (NASDAQ: AVIR) | Delayed: 5.45 +0.02 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.43 | 52 Week High | $2.00 | |||
| Open | $5.46 | 52 Week Low | $1.15 | |||
| Day High | $5.48 | P/E | N/A | |||
| Day Low | $5.38 | EPS | $0.00 | |||
| Volume | 9,382 | |||||
